GLPwatch
Papers (12034)
Page 79 of 201, ranked by citation count.
- Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI).
- Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates.
- Liraglutide in the treatment of obesity.
- Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.
- Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.
- Exenatide Use in the Management of Type 2 Diabetes Mellitus.
- Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction.
- Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis.
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
- Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
- GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion.
- Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
- Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
- Potential contributors to variation in weight-loss response to liraglutide.
- Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data.
- Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.
- Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
- Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese mice.
- Glucagon-like peptide-1 gene therapy.
- Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
- Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.
- Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers.
- The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells.
- Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
- Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
- Exenatide reduces oxidative stress and cell death in testis in iron overload rat model.
- Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
- Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy.
- Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
- Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
- A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.
- Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.
- Design, evaluation, and in vitro-in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide.
- Glucagon-like peptide-1 analogues for type 2 diabetes.
- Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats.
- The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways.
- Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice.
- Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
- Liraglutide abrogates nephrotoxic effects of chemotherapies.
- Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
- Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease.
- Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
- Why are we still in need for novel anti-obesity medications?
- Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.
- Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated.
- The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions.
- Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.
- C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.
- A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
- Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
- Dual factor delivery of CXCL12 and Exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions.
- The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes.
- Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.
- Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
- Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.
- The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.